20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs announced a rescheduled investor webinar to discuss its second quarter 2026 performance, highlighting record revenue growth from its multi-cancer early detection test, OneTest™. CEO Jonathan Cohen will detail the company's evolving test platform, successful state-funded cancer screening initiatives, and the strategic path toward regul…